TauRx Completes Successful Financing

The directors of TauRx Pharmaceuticals Ltd. are pleased to announce the successful completion of a US$70m rights issue financing from the company’s existing shareholders.  This financing, which was over-subscribed, will be used to implement a planned clinical study of the company’s LMTX product in patients with mild Alzheimer’s disease.